PATENT CLIFF MOMENT Semaglutide, a GLP-1 receptor agonist originally developed by Danish drugmaker Novo Nordisk, has redefined treatment paradigms for both diabetes and obesity by regulating blood sugar and suppressing appetite
HOLST: Oh it's interesting that in people with diabetes we have either too little insulin or too little insulin action, and usually too much glucagon, and that's one of the reasons that the blood glucose goes high, that they have too much glucagon at the wrong time
All these trials were designed to evaluate the primary outcome of 3-MACE defined as cardiovascular death, nonfatal myocardial infarct, and nonfatal stroke, except for the ELIXA trial of exenatide ER, which included hospitalization for unstable angina as an additional component of the 4-MACE composite outcomes
When Randy Marsh declares, Obesity is a goldmine! he echoes real executives whove turned health crises into revenue streams